High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm – a Pilot Study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00070681" target="_blank" >RIV/65269705:_____/19:00070681 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/19:00112977

Result on the web

<a href="https://www.linkos.cz/files/klinicka-onkologie/453/5502.pdf" target="_blank" >https://www.linkos.cz/files/klinicka-onkologie/453/5502.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amko2019109" target="_blank" >10.14735/amko2019109</a>

Result language

angličtina

Original language name

High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm – a Pilot Study

Original language description

Background: Microparticles (MPs) are small (0.1-1 μm) cell-derived vesicles released during activation or apoptosis, with a surface-exposed phosphatidylserine along with antigens indicating the cellular origin. The level of MPs is known to be elevated in thromboembolic diseases and malignancies; it is believed that MPs are not only amplifying but can also initiate the thrombogenesis processes. BCR/ABL negative myeloproliferative neoplasms (MPNs) are clonal haematopoietic diseases, which include polycythemia vera, essential thrombocythemia and primary myelofibrosis. One of the main problems of MPN patients is high risk and incidence of thrombosis which affect the survival, quality of life and life expectancy. Patients and methods: The clinical significance of circulating MPs was assessed in a group of 179 patients with BCR/ABL-negative MPNs. Analysis of MPs was done using flow cytometry on 417 samples, and MPs procoagulation activity was performed using a functional assay called Zymuphen MP-activity (Hyphen Biomed, Neuville-sur-oise, France) on 274 samples. Results: Significantly higher absolute and relative count of platelet MPs was found in MPN patients when compared with healthy group, respectively (p = 0.001, p = 0.043). Erythrocyte MPs were also significantly higher in MPN patients than in the healthy group (p = 0.001). Procoagulation activity of MPs was as well significantly higher in patients compared to the control group (p = 0.001). Patients with primary myelofibrosis had decreased absolute and relative count of platelet MPs compared to polycythemia vera and essential thrombocythemia patients, respectively (p = 0.008, p = 0.014). Presence of JAK2V617F mutation was associated with higher absolute and relative count of platelet MPs, respectively (p = 0.045, p = 0.029). Conclusion: Although some literature data support the hypothesis of a direct relation between MPs and thrombotic events in MPN patients, further studies are needed to evaluate the clinical implication of MPs in the hypercoagulation state of MPN patients.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Klinická onkologie

ISSN

0862-495X

e-ISSN

—

Volume of the periodical

32

Issue of the periodical within the volume

2

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

8

Pages from-to

109-116

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85065117097